# Ticagrelor CytoSorb Hemoadsorption

> **NCT04131959** · NA · TERMINATED · sponsor: **CytoSorbents, Inc** · enrollment: 5 (actual)

## Conditions studied

- Emergent Cardiothoracic Surgery
- Bleeding
- Drug Removal

## Interventions

- **DEVICE:** CytoSorb 300 mL device

## Key facts

- **NCT ID:** NCT04131959
- **Lead sponsor:** CytoSorbents, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-29
- **Primary completion:** 2021-05-04
- **Final completion:** 2021-05-04
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Stalled study execution from the impact of the COVID-19 pandemic on the UK NHS
- **Last updated:** 2022-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04131959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04131959, "Ticagrelor CytoSorb Hemoadsorption". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04131959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*